Poster: AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
Year: 2021
Type: article
Authors: David Sallman, Adam Asch, Suman Kambhampati, Monzr Al Malki, Joshua Zeidner, William Donnellan, Daniel Lee, Paresh Vyas, Deepa Jeyakumar, Gabriel Mannis, Tiffany Tanaka, Wanxing Chai-Ho, Richard Larson, Andrew Whiteley, Guido Marcucci, Rami Komrokji, Guillermo Garcia-Manero, Joanna Van Elk, Ming Lin, Roy Maute, Jens-Peter Volkmer, Chris Takimoto, Mark Chao, Naval Daver
Institutions: Moffitt Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Research Medical Center, HCA Midwest Division, City Of Hope National Medical Center, City of Hope, UNC Lineberger Comprehensive Cancer Center, Tennessee Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, University of Oxford, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, Stanford Medicine, Stanford University, University of California San Diego, Moores Cancer Center, University of California, Los Angeles, University of Chicago, Baylor University Medical Center, The University of Texas MD Anderson Cancer Center, Gilead Sciences (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200337124